This has been possible only because of the breakthrough therapy designation for experimental drugs by the FDA. With this increased number of clinical trials, there are newer challenges being faced by the researchers.

In his Key-Note Speech, hear Mr. Suresh Ramu talk about the challenges faced, and the need of newer statistical approaches required to make a difference in the lives of the many people who are already affected by the disease and for those who might get affected in the future.